# Gene Modulation inCancer Cellular Models

> **NIH NIH P30** · BAYLOR COLLEGE OF MEDICINE · 2022 · $138,871

## Abstract

PROJECT SUMMARY: Gene Modulation in Cancer Cell Models (GMCCM) Shared Resource 
The complexity and heterogeneity of cancer demand appropriate and adaptable cell-based models that enable 
researchers to uncover key genes, pathways, interactions, and modifications that drive cancer development 
and to devise effective and personalized therapeutics. The Gene Modulation in Cancer Cell Models (GMCCM) 
Shared Resource provides DLDCCC members with a versatile combination of cutting-edge technologies, 
genomic resources, and advanced instrumentation. Directed by Drs. Dan Liu and Jean Kim, who combined 
have extensive expertise in developing technologies and cancer cell models (e.g., high-throughput genetic 
screens and stem cell manipulation), GMCCM houses essential elements for single-gene analyses to whole- 
genome screens, including genome-wide libraries of short-hairpin RNAs (shRNAs), cDNAs, and CRISPR 
sgRNAs, as well as multiple automated robotic platforms for library manipulation. In addition, the Shared 
Resource offers CRISPR/Cas9-mediated genome-editing services in a variety of cell types including induced 
pluripotent stem cells (iPSCs) derived from cancer patients. The ever-expanding functionalities of 
CRISPR/Cas9 that include gene targeting, genome modification, and transcriptional modulation, promise to 
greatly benefit DLDCCC members and facilitate both mechanistic and exploratory investigations using cancer 
cell models. Specific services provided by the GMCCM Shared Resource include cellular reprogramming, 
large-scale automated manipulation and preparation of genomic libraries, utilizing individual 
cDNA/shRNA/sgRNA vectors, and automated mammalian cell transfection and lentivirus production in arrayed 
formats. Importantly, GMCCM assists DLDCCC members with highly customizable gene-editing services in 
cells of their choice, from primary cells and established cell lines, to human pluripotent stem cells (hPSCs) and 
cancer patient-derived induced PSCs. By housing these resources in a single, cohesive Shared Resource, 
GMCCM allows investigators to employ myriad genomic and genetic platforms that are often cost- and labor- 
prohibitive or simply not feasible for individual laboratories. This synergistic combination of expertise and 
resources makes GMCCM an invaluable asset to the DLDCCC.

## Key facts

- **NIH application ID:** 10439813
- **Project number:** 5P30CA125123-16
- **Recipient organization:** BAYLOR COLLEGE OF MEDICINE
- **Principal Investigator:** Jun Xu
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $138,871
- **Award type:** 5
- **Project period:** 2007-07-01 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10439813

## Citation

> US National Institutes of Health, RePORTER application 10439813, Gene Modulation inCancer Cellular Models (5P30CA125123-16). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10439813. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*